Formation of gadolinium–ferritin from clinical magnetic resonance contrast agents-Reference-Cited by-同舟云学术

Formation of gadolinium–ferritin from clinical magnetic resonance contrast agents

Published:2020 Issue:12 Volume:2 Page:5567-5571
ISSN:2516-0230
Container-title:Nanoscale Advances
language:en
Short-container-title:Nanoscale Adv.

Author:

Neburkova Jitka¹²³^ORCID,Rulseh Aaron M.⁴⁵²³^ORCID,Chang Shery L. Y.⁶⁷⁸⁹¹⁰^ORCID,Raabova Helena¹²³,Vejpravova Jana¹¹¹²¹³¹⁴³^ORCID,Dracinsky Martin¹²³^ORCID,Tarabek Jan¹²³^ORCID,Kotek Jan¹¹¹²¹³¹⁴³^ORCID,Pingle Mohan⁴⁵²³,Majer Pavel¹²³,Vymazal Josef⁴⁵²³^ORCID,Cigler Petr¹²³^ORCID

Affiliation:

1. Institute of Organic Chemistry and Biochemistry of the CAS

2. Prague

3. Czechia

4. Department of Radiology

5. Na Homolce Hospital

6. Electron Microscopy Unit

7. Mark Wainwright Analytical Centre

8. and School of Materials Science and Engineering

9. University of New South Wales

10. Sydney

11. Department of Inorganic Chemistry

12. Faculty of Science

13. Charles University

14. 128 43 Prague 2

Abstract

We show that clinical gadolinium-based contrast agents can form Gd³⁺-ferritin nanoparticles under physiological conditions. We suggest they can contribute to the T₁ intensity changes in ferritin-rich brain areas observed in patients examined by MRI.

Funder

Ministerstvo Školství, Mládeže a Tělovýchovy

Ministerstvo Zdravotnictví Ceské Republiky

European Regional Development Fund

Publisher

Royal Society of Chemistry (RSC)

Subject

General Engineering,General Materials Science,General Chemistry,Atomic and Molecular Physics, and Optics,Bioengineering

Link

http://pubs.rsc.org/en/content/articlepdf/2020/NA/C9NA00567F

Reference50 articles.

1. 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives